The importance of measuring drug target residence times
Posted: 21 September 2015 | BioTek
The Synergy Neo2 Multi-Mode Reader is designed to provide high temporal resolution in drug target kinetics applications…


Target-based approaches to drug discovery have traditionally sought compounds of high binding affinity to the drug target. Affinity of inhibitory compounds is classically assessed using a labeled ligand which is competed from binding to the drug target. The important attributes of the inhibitory compound are its IC50 evaluated from inhibitor dose-response curves and its dissociation constant of binding, Ki as calculated from this empirical data using the Cheng-Prusoff equation, knowing the concentration of labeled ligand used in the assay and its equilibrium dissociation constant, Kd.
However, in recent years drug target kinetics has become an alternate method of evaluating inhibitors rather than the thermodynamic approach as outlined above. In these assays, the reciprocal of the inhibitor off rate, 1/koff, or the inhibitor residence time on the drug target, computed with the Motulsky and Mahan equation, becomes the important attribute. Various studies have shown that drug residence times are a promising early stage indicator of in vivo drug activity.
Accurately measuring inhibitor residence times requires detection of readouts with adequate temporal resolution to determine the key variables of the Motulsky and Mahan equation. This is particularly important for ratiometric readouts where the readout consists of a ratio of two signals. The Synergy Neo2 Multi-Mode Reader is designed to provide high temporal resolution in drug target kinetics applications, even with ratiometric measurements like HTRF®, by the simultaneous detection of time-resolved fluorescence at 620 and 665nm which provides improved temporal resolution and more accurate data than fast sequential measurements. With a high power Xe flashlamp for excitation that limits the number of flashes/measurement required for good sensitivity, along with its simultaneous detection capabilities, the Synergy Neo2 can provide temporal resolution < 1sec with high sensitivity for drug target kinetic studies…
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!
The rest of this article is restricted - login or subscribe free to access
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Assays, Drug Discovery, Kinetics
Related organisations
BioTek